Loading…
Loading…
Capital Investment Advisors LLC bought a new position in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 6,265 shares of the company's stock, valued at approximately $630,000. Several other large
IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.
Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's more compelling comeback stories.
Pharmaceutical stocks have been one of the best places to invest over the past year. Choosing between these two funds is really a question about how you want to own what comes next.
The iShares U.S. Pharmaceuticals ETF is significantly more concentrated than the State Street SPDR S&P Pharmaceuticals ETF, with Eli Lilly accounting for 23.63% of the portfolio. The iShares U.S. Pharmaceuticals ETF provides a higher dividend yield of 1.4% compared to 0.4% for the State Street SPDR S&P Pharmaceuticals ETF.
Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.
The iShares U.S. Pharmaceuticals ETF (IHE) was launched on May 1, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.
iShares U.S. Pharmaceuticals ETF offers concentrated exposure to US pharma, dominated by Johnson and Johnson (22.5%) and Eli Lilly and Company (20.5%). IHE benefits from structural growth in obesity therapies, robust drug pipelines, and demographic tailwinds but faces high concentration risk. Short-term catalysts include LLY's earnings momentum, FDA drug approvals, sector M&A activity, and potential interest rate improvements.